FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| APG777 | Atopic Dermatitis | PHASE2 | ACTIVE_NOT_RECRUITING |
| APG990 | Atopic Dermatitis | PHASE1 | ACTIVE_NOT_RECRUITING |
| Dupilumab | Atopic Dermatitis | PHASE1 | ACTIVE_NOT_RECRUITING |
APGE holds $105.6M in cash and burns about $63.5M/quarter from operations, giving an estimated runway of 5 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for APGE free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-08-11 | Fairmount Funds Management L |
Purchase | $5.6M |
| 2026-08-11 | Fairmount Funds Management L |
Purchase | $14.9M |
| 2026-08-11 | Fairmount Funds Management L |
Sale | $0 |
| 2026-08-07 | Dambkowski Carl |
Purchase | $4M |
| 2026-08-07 | Dambkowski Carl |
Sale | $22.6M |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for APGE and 2 more tickers of your choice.
Create Free Account →